Intraindividual Comparison of <sup>18</sup>F-PSMA-1007 with Renally Excreted PSMA Ligands for PSMA PET Imaging in Patients with Relapsed Prostate Cancer

Felix Dietlein, Carsten Kobe, Melanie Hohberg, Boris D. Zlatopolskiy, Philipp Krapf, Heike Endepols, Philipp Täger, Jochen Hammes, Axel Heidenreich, Thorsten Persigehl,

Journal of Nuclear Medicine · 2019 · 94 citations · 14 references

DOIFull text

Open access

Concepts

Abstract

<sup>18</sup>F-prostate-specific membrane antigen (PSMA)-1007 is excreted mainly through the liver. We benchmarked the performance of <sup>18</sup>F-PSMA-1007 against 3 renally excreted PSMA tracers. <b>Methods:</b> Among 668 patients, we selected 27 in whom PET/CT results obtained with <sup>68</sup>Ga-PSMA-11, <sup>18</sup>F-DCFPyL (2-(3-(1-carboxy-5-[(6-[<sup>18</sup>F]fluoro-pyridine-3-carbonyl)-amino]-pentyl)-ureido)-pentanedioic acid), or <sup>18</sup>F-JK-PSMA-7 (JK, Juelich-Koeln) were interpreted as equivocal or negative or as oligometastatic disease (PET-1). Within 3 wk, a second PET scan with <sup>18</sup>F-PSMA-1007 was performed (PET-2). The confidence in the interpretation of PSMA-positive locoregional findings was scored on a 5-point scale, first in routine diagnostics (reader 1) and then by an independent second evaluation (reader 2). Discordant PSMA-positive skeletal findings were examined by contrast-enhanced MRI. <b>Results:</b> For both readers, <sup>18</sup>F-PSMA-1007 facilitated the interpretability of 27 locoregional lesions. In PET-2, the clinical readout led to a significantly lower number of equivocal locoregional lesions (<i>P</i> = 0.024), and reader 2 reported a significantly higher rate of suspected lesions that were falsely interpreted as probably benign in PET-1 (<i>P</i> = 0.023). Exclusively in PET-2, we observed a total of 15 PSMA-positive spots in the bone marrow of 6 patients (22%). None of the 15 discordant spots had a morphologic correlate on the corresponding CT scan or on the subsequent MRI scan. Thus, <sup>18</sup>F-PSMA-1007 exhibits a significantly higher rate of unspecific medullary spots (<i>P</i> = 0.0006). <b>Conclusion:</b><sup>18</sup>F-PSMA-1007 may increase confidence in interpreting small locoregional lesions adjacent to the urinary tract but may decrease the interpretability of skeletal lesions.

References

14